Introduction {#s1}
============

Cancer is one of the most serious public health problems globally. In 2018, approximately 18.1 million new cancer cases and 9.6 million cancer-related deaths occurred in the world ([@B8]). There is an urgent need for a more effective therapy. Traditional Chinese medicine (TCM) has been used for thousands of years in Asia for its good efficacy and compliance, and this also made it an important supplemental medicine in cancer treatment ([@B220]). Comparing with the current "one drug, one target" mode, TCM has the feature of "multiple active ingredients, multiple targets" ([@B99]). Given that cancer is a complex disease which alters a range of cellular and molecular processes, TCM may hold the advantage of targeting multiple cancer-related molecules simultaneously with potential synergistic effects. However, as a result of the feature of "multiple ingredients, multiple targets", herbs can potentially interact with prescription medications like when cancer patients use plant-based regimens with chemotherapy ([@B234]; [@B153]; [@B154]). Therefore, the potential risk of using TCM as complementary medicine should be considered for maximum safety and efficacy.

*Litchi chinensis Sonn* (Litchi), a member of Litchi, Sapindaceae family, is a subtropical evergreen plant which has been widely cultivated as an economic cultivar for its delicious taste and rich nutrition fruitage in China, Philippines, Indonesia, and Vietnam ([@B143]; [@B140]). In China, Litchi seeds were used as an analgesic agent for the alleviation of neuralgia, orchitis, testicular swelling, hernia, gastralgia, lumbago, abdominal pain, etc. ([@B91]). The decoctions of Chinese herbal formula containing Litchi seeds were used as indigenous remedies for urologic neoplasms including prostate cancer, bladder cancer, and renal carcinoma ([@B177]; [@B212]). Moreover, a considerable amount of studies have shown that in addition to Litchi seeds, the extracts and ingredients from other parts (peels, pulps, and flowers) of Litchi can exert multiple pharmacological actions which have the anti-inflammatory ([@B28]), anti-oxidative ([@B95]), anti-bacterial ([@B232]), anti-viral ([@B43]; [@B225]), anti-liver injury, and immune-enhancing effects ([@B149]; [@B64]; [@B230]; [@B65]; [@B68]; [@B186]; [@B221]; [@B162]). Furthermore, there was accumulating evidence indicating that the extracts and compounds from Litchi exhibit anticancer effects by targeting multiple proteins and signal pathways involved in cancer cell proliferation, metastasis, angiogenesis, apoptosis, autophagy, etc. However, current studies are limited to the traditional research method of identifying "single-drug, single-target, and single-pathway", which failed to reflect the "multiple ingredients-multiple targets-multiple pathways" anticancer effects of Litchi. In order to elucidate its multiple modes of action, network pharmacology and bioinformatics were employed in this study as a powerful approach ([@B250]) to systematically analyze the complicated interactions between Litchi ingredients and confirmed targets based on published research results. This study has provided a solid base for the further exploration of its anticancer effects.

Methods {#s2}
=======

We collected the anticancer ingredients and targets of Litchi based on original published articles. In order to systematically analyze the complex relationships between these anticancer ingredients and their targets, an interaction network was constructed by network pharmacology approach. All networks maps were visualized and analyzed by Cytoscape 3.2.1 (<http://www.cytoscape.org/>). As shown in the ingredient-target network ([**Figures 1A**](#f1){ref-type="fig"}, [**2A**](#f2){ref-type="fig"}, [**3A**](#f3){ref-type="fig"}, [**4A**](#f4){ref-type="fig"}, and [**5**](#f5){ref-type="fig"}), the oval nodes represent ingredients, the rectangle nodes represent targets and each edge linking an ingredient to a target indicates a regulator-target relationship. In [**Figures 1A**](#f1){ref-type="fig"}--[**4A**](#f4){ref-type="fig"}, the targets distributing in the inner orange circle (rectangle) can be modulated by multiple ingredients rather than a single ingredient. The "degree" is an important parameter for the network pharmacology approach, which represents the number of related nodes to a particular node in the network. The greater the degree of a node, the more biologically important it is. Therefore, the top ingredients and targets were screened out by the Network Analyzer in Cytoscape based on the major parameter of "degree". To further explore the core biological processes of the top targets involved, we performed KEGG pathway enrichment analysis (<http://www.kegg.jp/>) and screened out the top signal pathways based on the P-value. The relationships among top targets, corresponding ingredients and signal pathways were analyzed by combining Cytoscape 3.2.1 with KEGG pathway enrichment analysis. In order to test the reliability of the top ingredient-target interactions and explore the accurate binding modes, we performed molecular docking analysis by using surflex module of Sybyl X2.0. A total score greater than 6 represents good protein-ligand binding. The crystal structures of proteins (targets) were extracted from Protein Data Bank (<https://www.rcsb.org/>).

![Ingredient-Target Network of Litchi Anti-Proliferation. **(A)** Network of 13 ingredients (oval) and 100 corresponding targets (rectangle). **(B)** The histogram of "ingredient and corresponding target number". **(C)** The ingredient-top target-signal pathway network. The round rectangle nodes (orange) correspond to 4 top targets, ellipse nodes (pink) are 11 ingredients acting on top targets, the size of the nodes is illustrated from small to big in ascending order of degree values, the hexagon nodes (blue) represent signal pathways enriched based on top targets. **(D)** The top 10 pathway based on KEGG enrichment analysis.](fphar-11-00451-g001){#f1}

![Ingredient-Target Network of Litchi Inducing Cancer Cell Apoptosis and Autophagy. **(A)** The ingredient-target network of 18 ingredients (oval) associated with 138 targets (rectangle). **(B)** The histogram of "ingredient and corresponding target number". **(C)** The ingredient-top target-signal pathway network. The round rectangle nodes (orange) represent 6 top targets, ellipse nodes (pink) represent 18 ingredients acting on top targets, the size of the nodes is illustrated from small to big in ascending order of degree values, the hexagon nodes (blue) represent signal pathways enriched based on top targets. **(D)** The top 10 pathways based on KEGG enrichment analysis.](fphar-11-00451-g002){#f2}

![Ingredient-Target Network of Litchi Inhibiting Cancer Metastasis. **(A)** The ingredient-target network of 9 ingredients (oval) associated with 99 targets (rectangle). **(B)** The histogram of "ingredient and corresponding target number". **(C)** The ingredient-top target-signal pathway network. The round rectangle nodes (orange) represent 2 top targets, ellipse nodes (pink) represent 8 ingredients acting on top targets, the size of the nodes is positively related to their degrees in the network, the hexagon nodes (blue) represent signal pathways enriched based on top targets. **(D)** The top 5 pathways based on KEGG enrichment analysis.](fphar-11-00451-g003){#f3}

![Ingredient-Target Network of Litchi Sensitizing Chemotherapy and Radiotherapy. **(A)** The ingredient-target network of 12 ingredients (oval) and 106 targets (rectangle). **(B)** The histogram of "ingredient and corresponding target number". **(C)** The ingredient-top target-signal pathway network. The round rectangle nodes (orange) are top targets, ellipse nodes (pink) represent ingredients acting on top targets, the node size of ingredients is proportional to the degree values, the hexagon nodes (blue) represent signal pathways enriched based on top targets. **(D)** The top 10 pathways based on KEGG enrichment analysis.](fphar-11-00451-g004){#f4}

![Ingredient-Target Network of Litchi Inhibiting Cancer Stemness, Metabolism, Angiogenesis, and Enhancing Immunity. **(A)** The ingredient-target network involving in cancer stemness. Different colors of ovals indicate 4 ingredients, the rectangle nodes represent 16 targets. **(B)** The ingredient-target networks involving cancer metabolism. Different colors of ovals indicate 5 ingredients, the rectangle nodes represent 23 targets. **(C)** The ingredient-target networks involving angiogenesis. Different colors of ovals indicate 6 ingredients, the rectangle nodes represent 12 targets. **(D)** The ingredient-target networks involving cancer immunity. Different colors of ovals indicate 3 ingredients, the rectangle nodes represent 18 targets.](fphar-11-00451-g005){#f5}

Results {#s3}
=======

Ingredients From Litchi {#s3_1}
-----------------------

Litchi contains a variety of natural products, such as anthocyanins, flavonoids, phenolic acids, terpenes, fatty acids, sterols, lignans, coumarins, and esters. A total of 110 compounds (32 Anthocyanins, 32 Flavonoids, 9 Phenolic acids, 9 Tocotrienols, 8 Lignans, 4 Alcohols, 4 Sterols, 3 Triterpenes, 3 Fatty Acids, 2 Esters, 2 Glycosides, 1 Furfurals, 1 Coumarins) isolated from Litchi have been reported, which were summarized in [**Table 1**](#T1){ref-type="table"} according to the parts (peels, pulps, seeds, leaves, and flowers) of Litchi, with their molecular formulae, structure category and corresponding reference (Ref). As shown in [**Table 1**](#T1){ref-type="table"}, various kinds of chemical constituents were isolated from its peels (28 compounds), pulps (12 compounds), seeds (49 compounds) leaves (28 compounds), and flowers (1 compound). Among them, we identified flavonoids and anthocyanins which were mostly found in Litchi peels, seeds, and leaves to be the main compounds.

###### 

Compounds Isolated from *L. chinensis*.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parts         No                                                                               Ingredients             Formula           Compound yield (mg/100g)   Category       Ref
  ------------- -------------------------------------------------------------------------------- ----------------------- ----------------- -------------------------- -------------- -----------
  **Peels**     1                                                                                Cyanidin-3-rutinoside   C~27~H~31~O~15~   1.29--19.11                Anthocyanins   ([@B101])

  2             Cyanidin-3-glucoside                                                             C~21~H~21~O~11~         0.80--1.80        Anthocyanins               ([@B101])      

  3             Quercetin-3-glucoside                                                            C~21~H~20~O~12~         5.00              Anthocyanins               ([@B135])      

  4             Malvidin-3-glucoside                                                             C~23~H~25~O~12~         0.67--1.98        Anthocyanins               ([@B101])      

  5             Epigallocatechin gallate (EGCG)                                                  C~22~H~18~O~11~         /                 Anthocyanins               ([@B224])      

  6             Dehydrodiepicatechin A                                                           C~30~H~24~O~12~         0\. 50            Anthocyanins               ([@B135])      

  7             Procyanidin A2                                                                   C~30~H~24~O~12~         68.30             Anthocyanins               ([@B172])      

  8             Proanthocyanidin A1                                                              C~31~H~24~O~12~         0\. 64            Anthocyanins               ([@B135])      

  9             Epicatechin-(4β→8,2β→O→7)-epicatechin-(4β→8)-epicatechin                         C~45~H~36~O~18~         /                 Anthocyanins               ([@B118])      

  10            Proanthocyanidin B2                                                              C~30~H~26~O~12~         1.02              Anthocyanins               ([@B246])      

  11            Proanthocyanidin B4                                                              C~30~H~26~O~12~         0.48              Anthocyanins               ([@B246])      

  12            Bis(8-epicatechinyl) methane                                                     C~31~H~28~O~12~         0\. 30            Anthocyanins               ([@B135])      

  13            8-(2-pyrrolidinone-5-yl)-(−)-epicatechin                                         C~19~H~14~O~7~N         0\. 16            Anthocyanins               ([@B135])      

  14            (−)-epicatechin 8-C-β-D-glucopyranoside                                          C~21~H~20~O~11~         0\. 08            Anthocyanins               ([@B135])      

  15            Naringenin7-O-(2,6-O-α-L-rhamnopyranosyl)-β-Dglucopyranoside                     C~30~H~40~O~11~         0\. 30            Anthocyanins               ([@B135])      

  16            (-)-Epigallocatechin (EGC)                                                       C~15~H~14~O~6~          97.30             Anthocyanins               ([@B246])      

  17            Rutin                                                                            C~27~H~30~O~16~         0\. 44            Flavonoids                 ([@B135])      

  18            Epiafzelechin                                                                    C~15~H~14~O~5~          /                 Flavonoids                 ([@B257])      

  19            (-)-Epicatechin (EC)                                                             C~15~H~14~O~6~          0\. 22            Flavonoids                 ([@B135])      

  20            (-)-Gallocatechin (GC)                                                           C~15~H~14~O~7~          22.90             Flavonoids                 ([@B246])      

  21            Epicatechin glucoside                                                            C~21~H~24~O~11~         /                 Flavonoids                 ([@B257])      

  22            Kaempferol                                                                       C~15~H~10~O~6~          0\. 33            Flavonoids                 ([@B74])       

  23            Naringenin                                                                       C~15~H~12~O~5~          0\. 30            Flavonoids                 ([@B135])      

  24            Isolariciresinol                                                                 C~20~H~24~O~6~          0\. 60            Lignans                    ([@B74])       

  25            Methyl-3,4-dihydroxybenzoate                                                     C~8~H~8~O~4~            0\. 40            Phenolic acids             ([@B74])       

  26            2-(2-Hydroxy-5-(methoxycarbonyl) phenoxy)benzoic acid                            C~15~H~12~O~6~          1.68              Phenolic acids             ([@B74])       

  27            Stigmasterol                                                                     C~29~H~48~O             0\. 70            Sterols                    ([@B74])       

  28            Methylshikimate                                                                  C~8~H~12~O~5~           25.50             Esters                     ([@B74])       

  29            Ethyl shikimate                                                                  C~9~H~14~O~5~           3.75              Esters                     ([@B74])       

  **Pulps**                                                                                                                                                                          

  30            Propelargonidin                                                                  C~30~H~26~O~12~         /                 Anthocyanins               ([@B132])      

  31            Prodelphinidin                                                                   C~45~H~36~O~21~         /                 Anthocyanins               ([@B132])      

  32            Procyanidin                                                                      C~30~H~26~O~18~         /                 Anthocyanins               ([@B132])      

  33            (+)-Catechin                                                                     C~15~H~14~O~6~          0.02--0.11        Flavonoids                 ([@B247])      

  19            (-)-Epicatechin (EC)                                                             C~15~H~14~O~6~          2.31              Flavonoids                 ([@B185])      

  34            Quercetin-3-O-rutinoside-7-O-α-L-rhamnoside                                      C~33~H~40~O~20~         17.25             Flavonoids                 ([@B185])      

  35            (24R)-5α-stigmast-3, 6-dione                                                     C29H48O2                /                 Flavonoids                 ([@B195])      

  36            Caffeic acid                                                                     C~9~H~8~O~4~            0.02--0.14        Phenolic acids             ([@B247])      

  37            Chlorogenic acid                                                                 C~16~H~18~O~9~          0.06--0.18        Phenolic acids             ([@B247])      

  38            5-Hydroxymethyl-2-furfurolaldehyde\                                              C~6~H~6~O~3~            0\. 51            Furfurals                  ([@B258])      
                (5-HMF)                                                                                                                                                              

  39            Benzyl alcohol                                                                   C~7~H~8~O               0\. 15            Alcohols                   ([@B258])      

  40            Hydrobenzoin                                                                     C~14~H~14~O~2~          0\. 99            Alcohols                   ([@B258])      

  **Seeds**                                                                                                                                                                          

  7             Procyanidin A2                                                                   C~30~H~24~O~12~         0.18              Anthocyanins               ([@B225])      

  8             Proanthocyanidin A1                                                              C~31~H~24~O~12~         0.14              Anthocyanins               ([@B225])      

  41            Proanthocyanidin A6                                                              C~31~H~28~O~12~         0.19              Anthocyanins               ([@B225])      

  42            Aesculitannin A                                                                  C~45~H~36~O~18~         0.26              Anthocyanins               ([@B225])      

  43            Litchitannin A1                                                                  C~45~H~34~O~18~         0.14              Anthocyanins               ([@B225])      

  44            Litchitannin A2                                                                  C~45~H~34~O~18~         0.18              Anthocyanins               ([@B225])      

  45            2α,3α-Epoxy-5,7,3\`,4\`-tetrahydroxyflavan-(4β-8-catechin)                       C~30~H~24~O~12~         2.40              Anthocyanins               ([@B200])      

  46            Epicatechin-(2β→O→7,4β→8)-epiafzelechin-(4α→8)-epicatechin                       C~45~H~36~O~17~         0.29              Anthocyanins               ([@B226])      

  47            2β,3β-Epoxy-5,7,3\`,4\`-tetrahydroxyflavan-(4α-8-epicatechin)                    C~30~H~24~O~12~         1.07              Anthocyanins               ([@B200])      

  48            2α,3α-Epoxy-5,7,3\`,4\`-tetrahydroxyflavan-(4β-8-epicatechin)                    C~30~H~24~O~12~         3.52              Anthocyanins               ([@B200])      

  49            Litchiol A                                                                       C~21~H~32~O~10~         0.37              Anthocyanins               ([@B200])      

  50            Litchiol B                                                                       C~9~H~12~O~6~           0.07              Anthocyanins               ([@B200])      

  51            (-)-Epicatechin-3-gallate (ECG)                                                  C~22~H~18~O~0~          /                 Anthocyanins               ([@B158])      

  52            Epicatechin-(7,8-bc)-4β-(4hydroxyphenyl)-dihydro-2(3H)-pyranone                  C~24~H~20~O~8~          0.29              Flavonoids                 ([@B225])      

  53            Quercetin                                                                        C~15~H~10~O~7~          /                 Flavonoids                 ([@B166])      

  54            Pinocembrin-7-O-\[(2\`\`,6\`\`-di-O-α-L-rhamnopyranosyl)-β-D-glucopyranoside\]   C~33~H~42~O~17~         /                 Flavonoids                 ([@B166])      

  55            (-)-Pinocembrin-7-O-neohesperidoside (Onychin)                                   C~27~H~32~O~13~         /                 Flavonoids                 ([@B166])      

  56            Kaempferol-7-O-neohesperidoside                                                  C~27~H~30~O~15~         0.13              Flavonoids                 ([@B225])      

  57            Tamarixetin 3-O-rutinoside                                                       C~28~H~32~O~16~         0.39              Flavonoids                 ([@B225])      

  58            Kaempferol-7-O-β-D-glucopyranoside                                               C~21~H~20~O~11~         /                 Flavonoids                 ([@B166])      

  59            Pinocembrin-7-O-glucoside                                                        C~21~H~22~O~8~          /                 Flavonoids                 ([@B166])      

  60            (2S)-Pinocembrin-7-O-(6-O-α-L-rhamnopyranosyl-β-D-glucopyranoside)               C~27~H~32~O~13~         0\. 03            Flavonoids                 ([@B165])      

  61            Naringin                                                                         C~27~H~32~O~14~         0.30              Flavonoids                 ([@B200])      

  62            (2R)-Pinocembrin-7-neohesperidoside                                              C~27~H~32~O~13~         0.69              Flavonoids                 ([@B200])      

  63            Dihydrocharcone-4\`-O-β-D-glucopyranoside                                        C~21~H~24~O~10~         0.57              Flavonoids                 ([@B200])      

  64            (2R)-Naringenin-7-O-(3-O-α-L-rhamnopyranosyl-β-D-glucopyranoside)                C~27~H~32~O~14~         0.08              Flavonoids                 ([@B165])      

  65            Litchioside D                                                                    C~33~H~42~O~17~         0.28              Flavonoids                 ([@B225])      

  66            Pinocembrin-7-O-\[(6\`\`-O-β-D-glucopyranoside)-β-D-glucopyranoside\]            C~27~H~32~O~14~         /                 Flavonoids                 ([@B166])      

  67            Narcissin                                                                        C~28~H~32~O~16~         /                 Flavonoids                 ([@B166])      

  68            Taxifolin-4\`-O-β-D-glucopyranoside                                              C~21~H~22~O~13~         0.70              Flavonoids                 ([@B225])      

  69            (2S)-Pinocembrin-7-O-(6\`\`-O-α-L-arabinosyl-β-D-glucopyranoside)                C~26~H~30~O~13~         /                 Flavonoids                 ([@B252])      

  70            Phlorizin                                                                        C~21~H~24~O~10~         /                 Flavonoids                 ([@B166])      

  71            Scopoletin                                                                       C~10~H~8~O~4~           0.07              Coumarins                  ([@B200])      

  72            Protocatechuic acid (PA)                                                         C~7~H~6~O~4~            0.43              Phenolic acids             ([@B200])      

  73            Coumaric acid                                                                    C~9~H~8~O~3~            0.20              Phenolic acids             ([@B200])      

  74            Gallic acid                                                                      C~7~H~6~O~5~            /                 Phenolic acids             ([@B158])      

  75            Butylated hydroxytoluene                                                         C~14~H~22~O             3.80              Phenolic acids             ([@B74])       

  76            Litchioside A                                                                    C~31~H~52~O~10~         0.23              Lignans                    ([@B228])      

  77            Litchioside B                                                                    C~30~H~44~O~10~         0.10              Lignans                    ([@B225])      

  78            Pumilaside A                                                                     C~21~H~38~O~8~          0.39              Lignans                    ([@B225])      

  79            Funingensin A                                                                    C~21~H~36~O~7~          0.16              Lignans                    ([@B225])      

  80            Pterodontriol-D-6-O-β-D-glucopyranoside                                          C~21~H~38~O~18~         0.20              Lignans                    ([@B200])      

  81            Methyl dihydrosterculate                                                         C~20~H~38~O~2~          /                 Fatty Acids                ([@B184])      

  82            2,5-Dihydroxy-hexanoic acid                                                      C~6~H~12~O~4~           0.10              Fatty Acids                ([@B200])      

  83            Litchioside C                                                                    C~19~H~34~O~9~          0.60              Fatty Acids                ([@B228])      

  84            3-Oxotrirucalla-7,24-dien-21-oic acid                                            C~30~H~46~O~3~          0.88              Triterpenes                ([@B195])      

  38            5-Hydroxymethyl-2-furfurolaldehyde (5-HMF)                                       C~6~H~6~O~3~            0\. 51            Furfurals                  ([@B258])      

  39            Benzyl alcohol                                                                   C~7~H~8~O               0\. 15            Alcohols                   ([@B258])      

  40            Hydrobenzoin                                                                     C~14~H~14~O~2~          0\. 99            Alcohols                   ([@B258])      

  **Leaves**                                                                                                                                                                         

  7             Procyanidin A2                                                                   C~30~H~24~O~12~         2.00              Anthocyanins               ([@B188])      

  85            (-)-Pinocembrin 7-O-rutinoside                                                   C~27~H~32~O~13~         0.15              Anthocyanins               ([@B225])      

  86            Cinnamtannin B1                                                                  C~45~H~36~O~18~         1.18              Anthocyanins               ([@B216])      

  19            (-)-Epicatechin (EC)                                                             C~15~H~14~O~6~          27.76             Flavonoids                 ([@B214])      

  87            Luteolin                                                                         C~15~H~10~O~6~          0.10              Flavonoids                 ([@B214])      

  88            Kaempferol-3-O-β-D-glucoside                                                     C~21~H~20~O~11~         9.41              Flavonoids                 ([@B214])      

  89            Kaempferol-3-O-α-rhamnoside                                                      C~21~H~20~O~10~         0.13              Flavonoids                 ([@B214])      

  17            Rutin                                                                            C~27~H~30~O~16~         0.67              Flavonoids                 ([@B214])      

  90            Litchtocotrienol A                                                               C~27~H~42~O~4~          0\. 16            Tocotrienols               ([@B116])      

  91            Litchtocotrienol B                                                               C~28~H~44~O~5~          0\. 16            Tocotrienols               ([@B116])      

  92            Litchtocotrienol C                                                               C~28~H~44~O~4~          0.09              Tocotrienols               ([@B116])      

  93            Litchtocotrienol D                                                               C~29~H~46~O~5~          0.04              Tocotrienols               ([@B116])      

  94            Litchtocotrienol E                                                               C~27~H~40~O~3~          0.09              Tocotrienols               ([@B116])      

  95            Litchtocotrienol F                                                               C~28~H~42~O~4~          0.04              Tocotrienols               ([@B116])      

  96            Litchtocotrienol G                                                               C~28~H~42~O~5~          0.04              Tocotrienols               ([@B116])      

  97            Cyclolitchtocotrienol A                                                          C~27~H~40~O~4~          0\. 20            Tocotrienols               ([@B116])      

  98            Macrolitchtocotrienol A                                                          C~27~H~39~O~3~          0.02              Tocotrienols               ([@B116])      

  99            Schizandriside                                                                   C~25~H~32~O~10~         0.94              Lignans                    ([@B215])      

  100           4,7,7\`,8\`,9,9\`-Hexahydroxy-3,3\`-dimethoxy-8,4\`-oxyneolignan                 C~20~H~26~O~9~          0.56              Lignans                    ([@B216])      

  101           β-Sitosterol                                                                     C~29~H~50~O             /                 Sterols                    ([@B138])      

  102           Betulin                                                                          C~30~H~50~O~2~          /                 Sterols                    ([@B138])      

  103           Betulinic acid                                                                   C~29~H~48~O~3~          /                 Sterols                    ([@B138])      

  104           Lup-12,20(29)diene-3, 27-diol                                                    C~30~H~48~O~2~          0.15              Triterpenes                ([@B138])      

  105           Lupeol                                                                           C~30~H~50~O             /                 Triterpenes                ([@B138])      

  106           Secoisolariciresinol-9\`-O-β-D-xyloside                                          C~25~H~34~O~10~         0.41              Glycosides                 ([@B216])      

  107           Ehletianol C                                                                     C~30~H~36~O~10~         0.07              Glycosides                 ([@B215])      

  108           Sesquimarocanol                                                                  C~30~H~38~O~10~         0.61              Alcohols                   ([@B215])      

  109           Sesquipinsapol B                                                                 C~30~H~36~O~9~          0.10              Alcohols                   ([@B215])      

  **Flowers**                                                                                                                                                                        

  110           Gentisic acid                                                                    C~7~H~6~O~4~            /                 Phenolic acids             ([@B34])       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Multi-Targeted Anticancer Effects of Litchi Ingredients {#s3_2}
-----------------------------------------------------------

We summarized the confirmed anticancer ingredients of Litchi by going through each original published articles and found that 19 compounds (6 Anthocyanidins, 7 Flavonoids, 3 Phenolic acids, 2 Sterols, 1 Triterpenes) might inhibit cancer development through multifunctional mechanisms including regulation of cell proliferation, apoptosis, metabolism, metastasis, angiogenesis, stemness, and immunity. The anticancer ingredients with their corresponding effects, molecular targets, and cancer types were listed in [**Table 2**](#T2){ref-type="table"}. We then discovered that a single component could have a range of targets and different components had overlapping molecular targets, hence they formed a complicated regulatory network. In order to unravel this intricate web of interactions, we applied network pharmacology method to analyze the anticancer effects of Litchi from a perspective of system biology.

###### 

The Anticancer Ingredients and Targets from Litchi.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Category                                    Ingredients                                                                                                                                                                                                                                                               Effects                                                                                                                                                                                                               Targets                                                                                                                    Cancer types                                                                                                                      Ref
  ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- -----------------------------------
  **Anthocyanins**                            (-)-Epicatechin-3-gallate (ECG)                                                                                                                                                                                                                                           anti-proliferation                                                                                                                                                                                                    ATF3, CCNB1/D1/D3/E, CDC2/4/6, CDKN1A/1B/2B, GDF15, TP53, TRAF1                                                            pancreatic and colon cancer                                                                                                       ([@B5]; [@B110]; [@B78]; [@B26])

  promoting apoptosis                         AKT1, BAX, BCL2, CASP3, MAPK1, JNK, CDKN1A, TP53                                                                                                                                                                                                                          colon cancer                                                                                                                                                                                                          ([@B26])                                                                                                                                                                                                                                                     

  inhibiting metabolism                       G6PD, TKT                                                                                                                                                                                                                                                                 colon cancer                                                                                                                                                                                                          ([@B169])                                                                                                                                                                                                                                                    

  (-)-Epigallocatechin (EGC)                  promoting apoptosis                                                                                                                                                                                                                                                       BAX, BCL2                                                                                                                                                                                                             breast cancer                                                                                                              ([@B199])                                                                                                                         

  Epigallocatechin gallate (EGCG)             anti-proliferation                                                                                                                                                                                                                                                        AKT1, AP1, APAF1, ATM, BIRC5, CCNB1, CDC2, CDKN1A, CYC, DIABLO, EGFR, ERBB2/3, FAS, FASLG, GDF15, JNK1/2, MAPK1/14/3, MLH1, MSH2, MTCO2, MYC, NFKB, PARP1, PEG2, PGE2, PIK3CA, PRKAA2, PTEN, PTK2, SP1, TP53, XRCC6   pancreatic, lung, colorectal, breast, prostate, gastric, and ovarian cancer                                                ([@B187]; [@B88]; [@B201]; [@B92]; [@B130]; [@B42])                                                                               

  attenuating angiogenesis                    MPI, ACTA1, PECAM1                                                                                                                                                                                                                                                        lung cancer                                                                                                                                                                                                           ([@B32])                                                                                                                                                                                                                                                     

  inhibiting metastasis                       CDH1/2, CSRC, ERBB2, ESR2, MAPK8, MIR138, NFKB, PTK2, SLC22A5, SNAIL1/2, TJP1, VIM,                                                                                                                                                                                       lung, colon, breast, bladder, and prostate cancer                                                                                                                                                                     ([@B178]; [@B159]; [@B174]; [@B173]; [@B31]; [@B86]; [@B144]; [@B103]; [@B69]; [@B131])                                                                                                                                                                      

  promoting apoptosis and autophagy           AKT1, AP1, APAF1, ATM, BAD, BAX, BCL2/L1, BIRC5, CASP2/3/8/9, CCNB1, CDC2, CDKN1A, CYC, DIABLO, EGFR, ERBB2/3, FAS, FASLG, GDF15, JNK1/2, KRAS, MAPK1/14, MLH1, MSH2, MTCO2, MYC, NFKB, PARP1, PEG2, PGE2, PIK3CA, PRKAA2, PTEN, PTK2, SP1, TP53                          pancreatic, lung, colon, head and neck, breast, and bladder cancer                                                                                                                                                    ([@B179]; [@B151]; [@B31]; [@B79]; [@B11]; [@B104]; [@B131]; [@B70]; [@B148]; [@B45]; [@B213]; [@B126])                                                                                                                                                      

  sensitizing chemotherapy                    ABCG2/B1, ATP7A/B, BAX, BBC3, CASP3/7/9, CDKN1A, ERCC1, GSTP1, HDGF, HSPA5, IRS1, JAK3, LC3II, MAPK1, MIR155, NFKB, PARP1, PDZD3/K1, PGP, PMAIP1, RPS6KB1, RXRA, SFN, SLC22A5, SLC31A1/A2, STAT3, TFAP2A, VEGFA                                                           colorectal, oral, gastric, pancreatic, lung, ovarian, and cervical cancer                                                                                                                                             ([@B191]; [@B62]; [@B203]; [@B41]; [@B192]; [@B55]; [@B139]; [@B156])                                                                                                                                                                                        

  inhibiting metabolism                       HIF1A, HK2, LDHA, PFKM, PKM, SLC2A1, VEGFA                                                                                                                                                                                                                                breast cancer                                                                                                                                                                                                         ([@B259]; [@B213])                                                                                                                                                                                                                                           

  suppressing stemness                        ALDH1A1, CD44, CTNNB1, GSK3B, MYC, NANOG, OCT4, PROM1, STAT3                                                                                                                                                                                                              nasopharyngeal and lung cancer                                                                                                                                                                                        ([@B115])                                                                                                                                                                                                                                                    

  Proanthocyanidin B2                         promoting apoptosis                                                                                                                                                                                                                                                       AKT1, ATG5, BAX, BECN1, CASP3, LC3I/II, MTOR, PIK3CA                                                                                                                                                                  colorectal cancer                                                                                                          ([@B251])                                                                                                                         

  Cyanidin-3-glucoside                        anti-proliferation                                                                                                                                                                                                                                                        MKI67, MUCIN4                                                                                                                                                                                                         ovarian cancer                                                                                                             ([@B241])                                                                                                                         

  attenuating angiogenesis                    STAT3, VEGFA                                                                                                                                                                                                                                                              breast cancer                                                                                                                                                                                                         ([@B134])                                                                                                                                                                                                                                                    

  inhibiting metastasis                       CDH1/2, CJUN, CSRC, ERBB2, ESR2, MAPK8, MIR138, MMP2, NFKB, PLAU, PTK2, SLC22A5, SNAIL1/2, TIMP2, TJP1, VIM,                                                                                                                                                              breast and lung cancer                                                                                                                                                                                                ([@B227]; [@B107])                                                                                                                                                                                                                                           

  promoting apoptosis                         BCL2, CASP3                                                                                                                                                                                                                                                               breast cancer                                                                                                                                                                                                         ([@B22])                                                                                                                                                                                                                                                     

  Cyanidin-3-rutinoside                       inhibiting metastasis                                                                                                                                                                                                                                                     MMP2, PLAU, TIMP2, CJUN, NFKB,                                                                                                                                                                                        lung cancer                                                                                                                ([@B13])                                                                                                                          

  **Flavonoids**                              (+)-Catechin                                                                                                                                                                                                                                                              anti-proliferation                                                                                                                                                                                                    CCNA/B1, CDK2/4, JNK, MAPK1/9/14                                                                                           breast cancer                                                                                                                     ([@B29])

  promoting apoptosis                         CASP3/8/9, TP53                                                                                                                                                                                                                                                           cervical cancer                                                                                                                                                                                                       ([@B3])                                                                                                                                                                                                                                                      

  sensitizing chemotherapy                    SOD2, GSTA1                                                                                                                                                                                                                                                               pancreatic cancer                                                                                                                                                                                                     ([@B141])                                                                                                                                                                                                                                                    

  (-)-Epicatechin (EC)                        anti-proliferation                                                                                                                                                                                                                                                        AKT1, MAPK1, NFKB, RAS                                                                                                                                                                                                lung and pancreatic cancer                                                                                                 ([@B180]; [@B198])                                                                                                                

  promoting apoptosis                         BAX, BCL2, NFKB, CDKN1A                                                                                                                                                                                                                                                   colon cancer and lymphoma                                                                                                                                                                                             ([@B137]; [@B82])                                                                                                                                                                                                                                            

  sensitizing radiotherapy and chemotherapy   CHEK2, CDKN1A, CASP3, GADD45A, DDIT3                                                                                                                                                                                                                                      pancreatic, lung cancer, and glioblastoma                                                                                                                                                                             ([@B170]; [@B36])                                                                                                                                                                                                                                            

  \                                           \                                                                                                                                                                                                                                                                         \                                                                                                                                                                                                                     \                                                                                                                          \                                                                                                                                 
  \                                           \                                                                                                                                                                                                                                                                         \                                                                                                                                                                                                                     \                                                                                                                          \                                                                                                                                 
  \                                           \                                                                                                                                                                                                                                                                         \                                                                                                                                                                                                                     \                                                                                                                          \                                                                                                                                 
  \                                           \                                                                                                                                                                                                                                                                         \                                                                                                                                                                                                                     \                                                                                                                          \                                                                                                                                 
  Kaempferol                                  anti-proliferation                                                                                                                                                                                                                                                        AKT1, CCNA/B1/D1/E, CDC2/25C, CDK1/2/20/4/5R1, CDKN1A, CHEK1/2, CMET, DNMT3B, ERBB3, ERRA, ERRG, GTF2H2, HIF1A, IGF1/1R, MAP1LC3A, MAPK1/14/3, MCL1, MIR21/340, MTOR, PIK3CA/R1, PRKAA2, PTEN, SQSTM1, TP53, USF2     bladder, breast, cervical, lung, colon, gastric, and liver cancer                                                          ([@B23]; [@B100]; [@B145]; [@B202]; [@B20]; [@B63]; [@B93]; [@B27]; [@B84]; [@B160]; [@B35]; [@B49]; [@B219]; [@B260]; [@B244])   

  attenuating angiogenesis                    AKT1, ESRRA, HIF1A, VEGFA                                                                                                                                                                                                                                                 ovarian cancer                                                                                                                                                                                                        ([@B127])                                                                                                                                                                                                                                                    

  inhibiting metastasis                       AKT1, CDH1/2, CJUN, MAPK2/3, MIR21, MMP2/9, MTOR, MYC, PIK3CA, PTEN, PTK2, RAC1, RHOA, SMAD3, SNAIL1, VIM                                                                                                                                                                 breast, oral cancer, lung, liver, and renal carcinoma                                                                                                                                                                 ([@B114]; [@B77]) ([@B96]; [@B71]; [@B260])                                                                                                                                                                                                                  

  promoting apoptosis and autophagy           AKT1, ATG7, ATM, BAD, BAX, BCL2/L1, BECN1, BID, BIK, CASP3/7/8/9, CFLIP, CYC, DDIT3, EHMT2, EREG, ERN1, FAS, H2AX, JNK, LC3I/II/III, MAP2K1/2, MAPK1/3, MTCO2, TERT, TNFRSF10A                                                                                            bladder, breast, cervical, colon, colorectal, endometrial, gastric, lung, and ovarian cancer                                                                                                                          ([@B147]; [@B100]; [@B129]; [@B222]; [@B94]; [@B84]; [@B235]; [@B81]; [@B254]; [@B24]; [@B25]; [@B85]; [@B260]; [@B244])                                                                                                                                     

  sensitizing chemotherapy                    ABCC6, AKT1, BAX, BCL2/L1, BIRC5, CASP3/7/8/9/10, CDKN1A, FAS, JAK1, JNK, MAPK1/14, MYC, NFKB, PARP1, PIK3CA, ROS1, STAT3, TNFRSF10A, XIAP,                                                                                                                               ovarian, lung, and colorectal cancer                                                                                                                                                                                  ([@B128]; [@B90]; [@B167])                                                                                                                                                                                                                                   

  inhibiting metabolism                       SLC2A1/16A1                                                                                                                                                                                                                                                               breast cancer                                                                                                                                                                                                         ([@B4])                                                                                                                                                                                                                                                      

  enhancing immunity                          CSF2, MAP2K1, MAPK2/3, PKC, PLC                                                                                                                                                                                                                                           prostate cancer                                                                                                                                                                                                       ([@B6])                                                                                                                                                                                                                                                      

  Luteolin                                    attenuating angiogenesis                                                                                                                                                                                                                                                  NOTCH1, VEGFA                                                                                                                                                                                                         gastric cancer                                                                                                             ([@B239])                                                                                                                         

  inhibiting metastasis                       AKT1, CDH1/2, CTNNB1, CYCD1, HES1, HEY1, MIR384, MMP2/3/7/9/16, NFKB, NFKBIA, NOTCH1, PIK3CA, PTN, SNAIL1/2, STAT3, VIM                                                                                                                                                   gastric, pancreatic, breast, lung, and colorectal cancer                                                                                                                                                              ([@B15]; [@B67]; [@B117]; [@B240]; [@B233])                                                                                                                                                                                                                  

  promoting apoptosis                         AIF, AKT1, ANO1, AURKB, BANF1, BAX, BCL2/L1, BIRC5, CASP3/9, CCND1/E, CDKN1A, DEDD2, ENG, GAK, HSP90, HTERT, MAPK1/14/3, MCL1, MCL4, MIR107/139/155/21/224/301/340/34A/422A/5703/630, MTOR, MYC, NFE2L2, NFKBIA, NOTCH1, PIK3CA, PTPN6, SIRT1, STAT3, TET1, TP53, VRK1,   breast, colon, gastric, lung, pancreatic, and prostate cancer                                                                                                                                                         ([@B83]; [@B136]; [@B48]; [@B183]; [@B175]; [@B105]; [@B75]; [@B80])                                                                                                                                                                                         

  sensitizing chemotherapy                    BAX, BCL2/L1, CASP3/7/8/9, CCNE2, CDH2, FAS, GSTA1/2, HMOX1, JAK1, JNK, MAPK1/14, NFE2L2, NFKBIA, PARP1, PPARG, PRKAR2A, PTK2, PTPN11, RACK1, RELA, ROS1, SLC22A5, SNAIL1/2, STAT1/2/3, TWIST1, TYK2, VIM                                                                 ovarian, lung, colorectal, cervical, breast, ovarian, and liver cancer                                                                                                                                                ([@B196]; [@B19]; [@B161]; [@B190]; [@B231]; [@B21]; [@B33]; [@B206]; [@B123])                                                                                                                                                                               

  suppressing stemness                        BMI1, CCND1, CD44, FZD6, IL6, MYC, OCT4, PROM1, STAT3                                                                                                                                                                                                                     prostate and oral cancer                                                                                                                                                                                              ([@B197]; [@B50])                                                                                                                                                                                                                                            

  Naringenin                                  anti-proliferation                                                                                                                                                                                                                                                        CCND1, EREG, ESR2, MAPK1/14                                                                                                                                                                                           cervical, colon, colorectal cancer, and hepatocarcinoma                                                                    ([@B193]; [@B181]; [@B249])                                                                                                       

  inhibiting metastasis                       AKT1, CDH1, MAPK1/4, MMP2/9, NCL, NFKB, PKCZ, PKCE, RAC1, RHO, RHOA, SCN9A, SNAIL1/2, TGFB1, TWIST1, VIM                                                                                                                                                                  breast, lung, and bladder cancer                                                                                                                                                                                      ([@B108]; [@B249]; [@B12]; [@B2]; [@B51]; [@B256])                                                                                                                                                                                                           

  promoting apoptosis                         AKT1, MAP3K5, ATF3, BAX, BCL2, BIRC5, CASP3/9, JNK, MAPK1/3/14, TP53, RPS6KB1, ROS1, RPS6                                                                                                                                                                                 prostate, pancreatic, colon, breast, and gastric cancer                                                                                                                                                               ([@B182]; [@B111]; [@B152]; [@B209])                                                                                                                                                                                                                         

  sensitizing chemotherapy                    CDKN2A, BCL2, CASP3/9, BAX, PTK2, MAPK14                                                                                                                                                                                                                                  lung and pancreatic cancer                                                                                                                                                                                            ([@B150]; [@B98])                                                                                                                                                                                                                                            

  inhibiting metabolism                       AKT1, GTF2H2, MAP2K1/2, MAPK1, NFKB1, PIK3CA                                                                                                                                                                                                                              breast cancer                                                                                                                                                                                                         ([@B52])                                                                                                                                                                                                                                                     

  enhancing immunity                          GZMB, ID2, IFNG, IRF2, SMAD3/7                                                                                                                                                                                                                                            lung cancer and melanoma                                                                                                                                                                                              ([@B106])                                                                                                                                                                                                                                                    

  Naringin                                    anti-proliferation                                                                                                                                                                                                                                                        AKT1, BIRC5, CDKN1A, CTNNB1, EGFR, MAPK1, MIR126, MTOR, NFKB, PIK3CA, VCAM1                                                                                                                                           lung, cervical, gastric, and breast cancer                                                                                 ([@B102]; [@B163]; [@B237]; [@B17])                                                                                               

  promoting apoptosis                         BAX, CASP1/3/9, FADD, FAS, MTCO2, NFKB, TP53, CDKL2                                                                                                                                                                                                                       cervical and lung cancer                                                                                                                                                                                              ([@B164]; [@B242])                                                                                                                                                                                                                                           

  sensitizing chemotherapy                    ChIL3, BAX, BID, BIRC5/7, CASP3, CDKN1A/B, CYC, MRC1NFKB, PGP, TP53                                                                                                                                                                                                       breast, prostate, and ovarian cancer                                                                                                                                                                                  ([@B248]; [@B2]; [@B39])                                                                                                                                                                                                                                     

  Rutin                                       sensitizing chemotherapy                                                                                                                                                                                                                                                  PGP, ABCG2,                                                                                                                                                                                                           breast cancer                                                                                                              ([@B73])                                                                                                                          

  promoting apoptosis                         BAX, BCL2, CASP3/8/9, GSK3B, IKKB, CHUK, MK2, NFKB, MAPK14, TP53, PARP1, TNF                                                                                                                                                                                              colon and lung cancer                                                                                                                                                                                                 ([@B47]; [@B218]; [@B146])                                                                                                                                                                                                                                   

  suppressing stemness                        NANOG, POU5F1, SOX2                                                                                                                                                                                                                                                       lung cancer                                                                                                                                                                                                           ([@B229])                                                                                                                                                                                                                                                    

  **Phenolic acids**                          Chlorogenic acid                                                                                                                                                                                                                                                          anti-proliferation                                                                                                                                                                                                    MAPK1, ROS1                                                                                                                colon cancer                                                                                                                      ([@B58])

  promoting apoptosis                         AKT1, CCNA/B1/D1/D3/E, CDC2/25C, CDK1/2/4/6, CHEK1/2, CDKN2A/2B/1A/1B, MAPK1/8/14, PIK3CA, SKP2, BAX, BCL2, CASP3                                                                                                                                                         bladder, prostate, renal carcinoma, and breast cancer                                                                                                                                                                 ([@B30]; [@B229]; [@B210])                                                                                                                                                                                                                                   

  Gallic acid                                 anti-proliferation                                                                                                                                                                                                                                                        AKT1, CCNA/B1/D1/D3/E, CDC25C/2C, CDK2/4/6, CDKN1A/1B, CHEK1/2, INK4, MAPK1/14, P18, PIK3CA, SKP2                                                                                                                     bladder, prostate, and breast cancer                                                                                       ([@B59]; [@B97]; [@B109]; [@B171])                                                                                                

  attenuating angiogenesis                    AKT1, EGFR, HIF1A, MAPK1, PTEN, VEGFA                                                                                                                                                                                                                                     cervical and ovarian cancer                                                                                                                                                                                           ([@B53]; [@B171])                                                                                                                                                                                                                                            

  inhibiting metastasis                       AKT1, CDC42, CHUK, CJUN, EGFR, GRB2, IL6, MAPK81/2, JUN, MAPK2/3/14, MEKK3, MMP2/9, NFKB, PIK3CA, PKC, PTK2, RAC1, RAS, RELA, RHOA, RHOB, ROS1, SOS1, SRC, STAT3                                                                                                          oral, prostate, bladder, breast, and gastric cancer                                                                                                                                                                   ([@B56]; [@B57]; [@B89]; [@B54]; [@B16])                                                                                                                                                                                                                     

  promoting apoptosis                         AKT1, APAF1, ATM, ATR, BAK1, BAX, BCL2/L1, BIK, BRCA1, CASP3/8/9, CKII, CYC, EREG, GSH, H2AX, JNK, MDC1, MGMT, MTOR, PARP1, PRKDC, ROS1, RPS6KB1, TP53, XIAP                                                                                                              oral, prostate, pancreatic, cervical, lung, and esophageal cancer                                                                                                                                                     ([@B40]; [@B14]; [@B238]; [@B168]; [@B119]; [@B124]; [@B112])                                                                                                                                                                                                

  sensitizing chemotherapy                    APAF1, BAX, BCL2, CASP3, CCNA/B, CCND1, DIABLO, EGFR, HIF1A, IL6, JAK1, MTCO2, MYC, NOS2, PARP1, ROS1, SRC, STAT3, TP53, VEGFA, XIAP                                                                                                                                      lung and cervical cancer                                                                                                                                                                                              ([@B155]; [@B204]; [@B1])                                                                                                                                                                                                                                    

  Protocatechuic acid (PA)                    anti-proliferation                                                                                                                                                                                                                                                        FGF2, JNK, MAPK3/1/14, NFKB1, PTK2, RELA,                                                                                                                                                                             lung cancer                                                                                                                ([@B194])                                                                                                                         

  inhibiting metastasis                       AKT1, CDC42, CJUN, CXCL8, FGF2, FN1, IL6, MMP2/9, NCL, NFKB/IA, PIK3CA, PKCE, RAC1, RAS, RHOA/B, USF2, VEGFA                                                                                                                                                              breast, lung, liver, cervical, and prostate cancer                                                                                                                                                                    ([@B236]; [@B133])                                                                                                                                                                                                                                           

  promoting apoptosis and autophagy           BAX, BCL2, CASP3, LC3I/II, PARP1                                                                                                                                                                                                                                          lung and ovarian cancer                                                                                                                                                                                               ([@B194]; [@B223])                                                                                                                                                                                                                                           

  **Sterols**                                 Betulinic acid                                                                                                                                                                                                                                                            anti-proliferation                                                                                                                                                                                                    MIR27A, SP1, YY1, ZBTB10                                                                                                   lung and breast cancer                                                                                                            ([@B61]; [@B120])

  attenuating angiogenesis                    HIF1A, STAT3                                                                                                                                                                                                                                                              prostate cancer                                                                                                                                                                                                       ([@B125])                                                                                                                                                                                                                                                    

  promoting apoptosis                         AKT1, BAD, BAK1, BAX, BCL2, CDH1, CASP3/9, CYC, NFKBIB, CHUK, MKI67, PMAIP1, CDKN1A/1B, TP53, CDKL2, PARP1, PIK3CA, ROS1, TIMP2, XIAP                                                                                                                                     colon, gastric, colorectal, cervical, prostate, and pancreatic cancer                                                                                                                                                 ([@B176]; [@B243])                                                                                                                                                                                                                                           

  sensitizing chemotherapy                    BAX, BCL2, BIRC5, CASP12/3, CDK6, CTNNB1, DDIT3, EGFR, EIF2A, GSK3B, HK2, HSPA5, MAP1LC3B, MAPK1, PARP1, RB1, SQSTM1, STAT3, TYMS, VDAC1                                                                                                                                  breast and lung cancer                                                                                                                                                                                                ([@B87]; [@B9]; [@B211])                                                                                                                                                                                                                                     

  inhibiting metabolism                       CAV1, IKBA, LDHA/B, MYC, PDK1, RELA                                                                                                                                                                                                                                       breast cancer                                                                                                                                                                                                         ([@B76]; [@B243])                                                                                                                                                                                                                                            

  suppressing stemness                        NANOG, OCT4, PRKAA2, SOX2                                                                                                                                                                                                                                                 pancreatic cancer                                                                                                                                                                                                     ([@B189])                                                                                                                                                                                                                                                    

  β-Sitosterol                                promoting apoptosis                                                                                                                                                                                                                                                       BAX, BCL2, CASP3                                                                                                                                                                                                      gastric cancer                                                                                                             ([@B253])                                                                                                                         

  sensitizing chemotherapy                    AKT1, GSK3B, RELA, BAX, BCL2, SNAIL1, VIM                                                                                                                                                                                                                                 pancreatic cancer                                                                                                                                                                                                     ([@B10])                                                                                                                                                                                                                                                     

  **Triterpenes**                             Lupeol                                                                                                                                                                                                                                                                    anti-proliferation                                                                                                                                                                                                    AKT1, BCL2, CCNA2/B/D3, CDC2/26C, CDK2/N1A/N1B/N2A, CLAUDIN1, CTNNB1, MAPK1, MYC, PLK1, TCF4, TP53                         head and neck, colorectal, prostate, pancreatic, and cervical cancer                                                              ([@B121]; [@B7]; [@B38]; [@B207])

  inhibiting metastasis                       BCL2, CLAUDIN1, MMP2/9, MTCO2, NFKB, RELA, TP53                                                                                                                                                                                                                           colorectal and breast cancer                                                                                                                                                                                          ([@B205]; [@B208])                                                                                                                                                                                                                                           

  promoting apoptosis                         APAF1, BAX, BCL2, CASP3/9, EGFR, MKI67, PARP1, STAT3                                                                                                                                                                                                                      cervical, head and neck, lung, and prostate cancer                                                                                                                                                                    ([@B157]; [@B7]; [@B142])                                                                                                                                                                                                                                    

  sensitizing chemotherapy                    ABCG2, MAPK1, EIF2A, CASP3                                                                                                                                                                                                                                                colon cancer                                                                                                                                                                                                          ([@B18])                                                                                                                                                                                                                                                     

  enhancing immunity                          AKT1, BCL2, CTNNB1, IFNG, LAMP1, MAPK2/3, PIK3CA, PRF1                                                                                                                                                                                                                    gastric cancer                                                                                                                                                                                                        ([@B217])                                                                                                                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### Inhibition of Cancer Cell Proliferation {#s3_2_1}

Sustained proliferation is a hallmark of cancer cells, and the restoration of dysregulated signaling pathways has always been a target for cancer treatment. The extracts from Litchi peels, pulps, seeds, leaves have been shown to inhibit the proliferation of a variety of cancer cells ([@B66]; [@B44]; [@B255]). The 13 anti-proliferative compounds identified from Litchi and 100 regulated targets were summarized in [**Table S1**](#SM1){ref-type="supplementary-material"}. The detailed analysis of the top active ingredients, corresponding targets, and signal pathways affected was shown in [**Figure 1**](#f1){ref-type="fig"}.

In total, this ingredient-target network ([**Figure 1A**](#f1){ref-type="fig"}) was consisted of 113 nodes ([**Table S1**](#SM1){ref-type="supplementary-material"}) and the mean degree of all nodes in the network was 3.080. Overall, 3 out of the 13 anticancer compounds ([**Figure 1A**](#f1){ref-type="fig"}) had high degree distributions (kaempferol: degree=39, Epigallocatechin gallate (EGCG): degree=36, gallic acid: degree=22) and all of them modulated more than 20 targets, which marked their pharmacological importance. Notably, those targets have more than one regulator ([**Table S2**](#SM2){ref-type="supplementary-material"}). Apart from 1 target that was regulated by 10 ingredients, 4 targets were regulated by over 5 ingredients and 28 targets were regulated by 2--4 ingredients ([**Figure 1B**](#f1){ref-type="fig"}). Further, the 4 top targets (MAPK1, CDKN1A, MAPK14, AKT1) were screened out from [**Figures 1A, B**](#f1){ref-type="fig"}, whose degree values were more than two folds of the median degree of all nodes in the network. This suggested that multiple ingredients could potentially exert synergistic anti-proliferation effects. In particular, the interactions among the above 4 top targets and Litchi ingredients ([**Table S3**](#SM3){ref-type="supplementary-material"}) were analyzed in [**Figure 1C**](#f1){ref-type="fig"}. With the results shown in [**Figure 1C**](#f1){ref-type="fig"}, we could conclude that there were 11 out of 13 ingredients that could regulate the top targets with anti-proliferative effects. It was also confirmed that the top 4 targets played an important role in the anti-proliferative process. Particularly, kaempferol, EGCG, and gallic acid could regulate all the top targets, and this conclusion was similar to that in [**Figure 1A**](#f1){ref-type="fig"} where 3 ingredients mentioned above had outstanding pharmacological significance. To further clarify the anticancer mechanism of Litchi ingredients, the pathway enrichment analysis based on above 4 top targets was performed. There were 63 signaling pathways involved in the anti-proliferation effects of Litchi ingredients ([**Figure 1C**](#f1){ref-type="fig"} and [**Table S3**](#SM3){ref-type="supplementary-material"}), and FoxO, VEGF, Prolactin, ErbB, HIF-1, Toll-like receptor, TNF, Rap1, MAPK, and PI3K-Akt signaling pathways were the top 10 pathways according to their P values ([**Figure 1D**](#f1){ref-type="fig"}). All of the 4 top targets were elements of FoxO signaling pathway and 3 out of the top 4 targets were elements of other 9 top pathways. It indicated that these top 10 pathways might be the major signaling pathways that are responsible for the anti-proliferation effects of Litchi.

### Induction of Cancer Cell Apoptosis and Autophagy {#s3_2_2}

Apart from uncontrollable proliferation, resistance to cell death is another strategy employed by cancer cells to fuel its growth. Cancer cells have evolved a series of strategies to inhibit cell death while Litchi ingredients have been reported to have pro-apoptosis and pro-autophagy effects ([@B60]; [@B38]). Hence, we summarized data from literature and constructed the network ([**Figure 2A**](#f2){ref-type="fig"}) based on 18 ingredients from Litchi and 138 targets ([**Table S4**](#SM4){ref-type="supplementary-material"}) which related to cell apoptosis and autophagy. The network was consisted of 156 nodes and 283 edges altogether, representing the extensive interactions among 18 ingredients and 138 targets ([**Table S4**](#SM4){ref-type="supplementary-material"}). Not surprisingly, we found that the mean degree of node was 3.679 based on the topological analysis, suggesting that it was common for ingredients to have multiple targets. By referring to the mean degree, we identified 6 top ingredients with a median degree ≥20, namely luteolin, EGCG, kaempferol, gallic acid, betulinic acid, and chlorogenic acid, with the top 2 having over 40 targets. Hence, we concluded that those top 6 ingredients were likely to be crucial components in promoting apoptosis and autophagy. Further, in order to clearly elucidate if these targets were regulated by multiple ingredients, another analysis was performed in [**Figure 2B**](#f2){ref-type="fig"}, which showed that there were 3 targets regulated by over 10 ingredients, 9 targets were regulated by 5--10 ingredients and 33 targets were regulated by more than 2 ingredients ([**Figure 2B**](#f2){ref-type="fig"} and [**Table S2**](#SM2){ref-type="supplementary-material"}). From [**Figures 2A, B**](#f2){ref-type="fig"}, we next screened out the top 6 targets (BAX, BCL2, CASP3, CASP9, TP53, AKT1) based on their degrees in the ingredient-target network. As shown in [**Figure 2C**](#f2){ref-type="fig"} and [**Table S5**](#SM5){ref-type="supplementary-material"}, all of the top 6 targets could be regulated by luteolin and EGCG, and this implied that they had multiple anticancer activities. In addition, all the 18 ingredients involving in apoptosis and autophagy interacted with the top targets, which consolidated the importance of these top targets. KEGG enrichment analysis based on these 6 top targets showed that 39 signaling pathways were involved in the effects of inducing cancer cell apoptosis and autophagy ([**Figure 2C**](#f2){ref-type="fig"} and [**Table S5**](#SM5){ref-type="supplementary-material"}), while p53, Neurotrophin, Sphingolipid, PI3K-Akt, Thyroid hormone, MAPK, VEGF, HIF-1, TNF signaling pathway and Adrenergic signaling in cardiomyocytes were the top 10 pathways ([**Figure 2D**](#f2){ref-type="fig"}). Four out of these top 6 targets were elements of p53, Neurotrophin, Sphingolipid, and PI3K-Akt signaling pathways, which indicates that these four signaling pathways might be the major pathways responsible for anticancer effect by inducing apoptosis and autophagy.

### Inhibiting Metastasis {#s3_2_3}

Metastasis is another target in cancer therapeutic development due to its lethality ([@B122]). Litchi seed extracts could attenuate migration and invasion capabilities of PC3 and DU145 cells ([@B46]). Nine anti-metastasis ingredients of Litchi and 99 corresponding targets were listed in [**Table S6**](#SM6){ref-type="supplementary-material"}, the interaction network of which was shown in [**Figure 3A**](#f3){ref-type="fig"}. We found that the mean degree of nodes in the network was 3.296. Then we screened out 4 top ingredients, namely EGCG, gallic acid, luteolin, and PA, with a median ≥20 degrees, which acted on 41, 29, 22, and 21 targets respectively. Therefore these 4 top ingredients identified were likely to be crucial bioactive components to inhibit metastasis. In addition, among the 99 targets, the network showed that MMP2 had the largest number of ingredient-target interactions (degree value of 8), followed by MMP9 (degree value of 7), making them likely to perform anti-metastasis functions. The remaining targets with lower degree and less than two folds of the mean degree of all nodes were also included. Then, the targets regulated by multiple ingredients were analyzed with a similar approach for more information. As shown in [**Figure 3B**](#f3){ref-type="fig"} and [**Table S2**](#SM2){ref-type="supplementary-material"}, MMP2 and MMP9 were regulated by 8 and 7 ingredients respectively, followed by another 6 targets regulated by up to 5 ingredients and 26 targets regulated by 2 to 4 ingredients. The "ingredients-top targets-pathways" network ([**Figure 3C**](#f3){ref-type="fig"} and [**Table S7**](#SM7){ref-type="supplementary-material"}) was constructed for the purpose of confirming the significance of top 2 targets, and this network indicated that as much as 8 ingredients exerted the anti-metastasis function through modulating MMP2 and MMP9. However, the signaling pathways enriched by KEGG based on 2 top targets merely included bladder cancer, estrogen signaling pathway, leukocyte transendothelial migration, proteoglycans in cancer and pathways in cancer. Both the top 2 targets were elements of these 5 pathways ([**Figures 3C, D**](#f3){ref-type="fig"} and [**Table S6**](#SM6){ref-type="supplementary-material"}), which indicated these 5 pathways might be the key anti-metastasis mechanism of Litchi.

### Sensitizing Chemotherapy and Radiotherapy {#s3_2_4}

Chemotherapy and radiotherapy are two of the most common cancer treatments. Despite their clinical efficacy in clearing cancer cells, therapeutic resistance often inevitably occurs. Another reported effect of Litchi was that it sensitized chemotherapy and radiotherapy. Here we identified 12 compounds from Litchi and 106 corresponding molecular targets responsible for this function ([**Table S8**](#SM8){ref-type="supplementary-material"}), with the detailed interactions of the top ingredients, targets and signal pathways shown in the [**Figure 4**](#f4){ref-type="fig"}. From [**Figure 4A**](#f4){ref-type="fig"}, we screened out 5 top ingredients with a median degree ≥20, including luteolin, EGCG, kaempferol, gallic acid, and betulinic acid, which linked to as much as 35, 34, 25, 22, and 21 targets respectively. Not surprisingly, the mode of "multi-ingredients, multi-targets" was confirmed again by identifying CASP3, BAX, and BCL2 as the top targets, which had the degree values of 9, 8, 6 respectively, which were more than two folds of the median degree of all nodes in the network. In addition, there were another 32 targets regulated by more than 2 ingredients ([**Figure 4B**](#f4){ref-type="fig"} and [**Table S2**](#SM2){ref-type="supplementary-material"}), which implied that Litchi ingredients could overcome chemo- and radio-resistance through a "multi-compounds, multi-targets" mode with potential synergistic effects. The "ingredients-top targets-pathways" network ([**Table S9**](#SM9){ref-type="supplementary-material"}) confirmed the importance of CASP3, BAX, and BCL2 further. In [**Figure 4C**](#f4){ref-type="fig"}, 10 out of 12 ingredients that were involved in sensitizing chemotherapy and radiotherapy exerted anticancer activity through regulating the 3 top targets. Moreover, KEGG enrichment analysis of top 3 targets showed that 15 signaling pathways were involved in the chemotherapy and radiotherapy sensitization ([**Figure 4C**](#f4){ref-type="fig"} and [**Table S9**](#SM9){ref-type="supplementary-material"}). All of the top 3 targets were elements of Amyotrophic lateral sclerosis (ALS), Colorectal cancer, Apoptosis, Hepatitis B, Tuberculosis and pathways in cancer, and 2 out of the top 3 targets were elements of p53 signaling pathway, Toxoplasmosis, Sphingolipid, and Neurotrophin signaling pathway, which indicates that the 10 pathways mentioned above might be responsible for the anticancer effect of Litchi on chemotherapy and radiotherapy sensitization ([**Figure 4D**](#f4){ref-type="fig"}).

### Other Anticancer Effects {#s3_2_5}

Apart from the four effects exerted by Litchi ingredients for the major anticancer functions as listed above, several other targets were also found to be involved in the suppression of cancer stemness, metabolism, and angiogenesis, while also in the enhancement of immunity as listed in [**Table S10**](#SM10){ref-type="supplementary-material"}. However, the experiments validations on the anticancer effect of Litchi ingredients from these four aspects were very limited. Therefore, we only constructed a simple ingredient-target network map ([**Figure 5**](#f5){ref-type="fig"}). The results showed that these mechanisms involved a total of 10 active ingredients, among which 5 belonged to the top ingredients from the previous screening including betulinic acid, EGCG, luteolin, gallic acid, and kaempferol, which further illustrated their importance. At the same time, we suggest that the remaining 5 ingredients (chlorogenic acid, (-)-Epicatechin-3-gallate (ECG), naringenin, cyanidin-3-glucoside, lupeol) and their detailed mechanisms need to be further explored.

Discussion {#s4}
==========

Numerous studies have shown that Litchi contains a variety of anti-cancer ingredients, which act by multiple targeting. Emanuele and Ibrahim described Litchi's nutritional value and reviewed the anti-tumor components and targets of Litchi with detailed listing but lacked a systematic analysis ([@B72]; [@B37]). In the present study, we collected 110 compounds isolated from Litchi and found 19 components with anticancer effects based on 241 published research papers. The detailed information for each one of these compounds was listed in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"} with corresponding targets. Then the network pharmacology approach was applied to explore the complicated "multi-ingredients, multi-targets, multi-pathways" anticancer mechanisms of Litchi from a system biology perspective.

We identified the top ingredients, top targets, and top signaling pathways of Litchi with anticancer effect from four major aspects including anti-proliferation, cell death promotion, inhibition of metastasis, and sensitization of chemotherapy and radiotherapy. Further, in order to identify the primary ingredients and targets acting on all four anticancer functions listed above, we performed analysis ([**Figure 6**](#f6){ref-type="fig"} and [**Table S11**](#SM11){ref-type="supplementary-material"}) and found EGCG and gallic acid to be the top ingredients participating in all of the four anticancer functions ([**Figure 6A**](#f6){ref-type="fig"} and [**Table S11**](#SM11){ref-type="supplementary-material"}). Moreover, EGCG was also involved in the suppression of cancer stemness, cancer metabolism, and angiogenesis, while gallic acid was involved in attenuating angiogenesis ([**Table S10**](#SM10){ref-type="supplementary-material"}). These results suggest that they are likely to be the major anticancer ingredients in Litchi. Apart from that, we also found that kaempferol, luteolin, and betulinic acid were the top ingredients which carried out at least 2 of anticancer mechanisms ([**Figure 6A**](#f6){ref-type="fig"} and [**Table S11**](#SM11){ref-type="supplementary-material"}). After selecting the primary ingredients from the overlapping parts, we found that BAX, BCL2, and CASP3 were the common targets which could induce apoptosis, autophagy, and sensitization, while AKT1 was a common target to suppress proliferation and induce apoptosis ([**Figure 6B**](#f6){ref-type="fig"} and [**Table S11**](#SM11){ref-type="supplementary-material"}). To further study the interactions among top ingredients (EGCG and gallic acid) and top targets (BAX, BCL2, CASP3, and AKT1), a molecular docking study was carried out to elucidate their binding modes. The result indicated a high binding affinity between EGCG and 4 targets with all of their total score greater than 6. However, gallic acid showed a lower binding affinity with each of their total score less than 6, while, only 2 top targets had active binding pockets for gallic acid with a total score of more than 5 ([**Figure 7**](#f7){ref-type="fig"} and [**Table S12**](#SM12){ref-type="supplementary-material"}). We speculated that gallic acid might exert anticancer effects by indirectly interacting with the top targets. Other than identifying single ingredient and its corresponding effect or vice versa, we mapped the complex interactive network of the primary targets and ingredients from Litchi ([**Table S11**](#SM11){ref-type="supplementary-material"}). The results could be used to maximize the effects of Litchi ingredients by extracting only the identified functional components based on the principles of Component Formula, which is a new model to develop innovative TCM with the understanding of the effective ingredients and pharmacological mechanisms ([@B245]). Notably, we have also found that some of the top pathways screened out in this study have been experimentally verified, such as PI3K-Akt, Ras and MAPK signaling pathways etc. ([@B113]; [@B200]; [@B111]). Hence, we have collected and summarized the results from independent studies, and also investigated further into the complex network of the multiple active ingredients and targets of Litchi. This would help to guide people to further explore the potential cancer therapy values of Litchi.

![Overlaps of Top Ingredients and Targets Related to Anti-Proliferation, Inducing Apoptosis and Autophagy, Inhibiting Metastasis and Sensitizing. **(A)** Top ingredients. **(B)** Top targets.](fphar-11-00451-g006){#f6}

![The Binding Modes of Top Ingredients and Top Targets. **(A)** The binding modes of EGCG in the active pockets: a (BAX/PDB ID: 6EB6); b (BCL2/PDB ID: 4AQ3); c (CASP3/PDB ID: 6CL0); d (AKT1/PDB ID: 6HHG). **(B)** The binding modes of gallic acid in the active pockets: a (BAX/PDB ID: 5W5Z); b (BCL2/PDB ID: 5VAX); c (CASP3/PDB ID: 6CL0); d (AKT1/PDB ID: 6BUU).](fphar-11-00451-g007){#f7}

This study systematically explored the anti-cancer mechanisms of Litchi using network pharmacology methods. However, it was distinct from traditional network pharmacology research, in which, the components and targets of a natural herb were mainly predicted based on online databases, followed by experimental verification *in vitro* and *in vivo*. In contrast, in this study, experiments were not of necessity because the anti-cancer ingredients, targets, and their interactions have already been experimentally confirmed in published literature. Furthermore, we collected information from independent studies and transformed them into a systematic interaction network with further analysis of the top ingredients, top targets and possible signaling pathways. For the first time, the anti-cancer properties of Litchi were explored from a new "multi-ingredients, multi-targets, and multi-pathways" perspective. However, selecting the top ingredients and top targets by network pharmacological methods alone has limitations, such as that it could neither reflect the anticancer effect intensity of these top ingredients, nor indicate if there was a correlation between the effectiveness of the ingredients and their concentrations. Also, we could not compare the pharmacokinetic parameters which directly affect drug efficacy. Therefore, based on the results of this article, we would use these top ingredients as a "Component Formula" in a combinatory manner and to explore their anti-cancer effect with *in vitro* and *in vivo* experiments in the follow-up studies.
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